10943 results for 'rate recycl bind protein 4'

Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from at

Imagine a world where cancer treatment is no longer a blunt instrument but a precision-guided surgical strike, executed by the body's own immune system. For years, we have dreamed of 'smart' cells th

Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons

Interleukin signaling is involved in a number of biological processes, including cell growth and differentiation, inflammation and immunity. Interleukins are glycoproteins which act on hema

The angiotensin pathway is a pivotal hormonal system that plays a crucial role in regulating blood pressure and maintaining fluid and electrolyte balance within the body. This complex biochemical

Introduction to TNFRSF9 and Its Role in Immune ActivationTNFRSF9, also known as 4-1BB or CD137, is a co-stimulatory receptor expressed on the surface of T cells, natural killer (NK) cells

Exploring the Role of TIM-3/Gal-9 in Antiparasitic ImmunityIntroductionThe immune system is a complex network of cells and molecules that work together to defend the body against pathogens, including

What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destructio

CD16, also known as FcγRIII (Fc gamma receptor III), plays a crucial role in the immune system, serving as a receptor for the Fc region of immunoglobulin G (IgG). This receptor is a key player in

CD16, also known as FcγRIII (Fc gamma receptor III), plays a crucial role in the immune system, serving as a receptor for the Fc region of immunoglobulin G (IgG). This receptor is a key player in

PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune evas

SARS-CoV-2, the causative viral agent of the novel coronavirus disease COVID-19, has sparked a global effort for creating prophylactic and therapeutic interventions. The following

By Shane Houston, PhD Candidate Queen’s University Belfast Cancer is an age old adversary of the human race. This out-of-control growth of abnormal cells has been a shadow over human health t

What You Need to Know About OzuriftamabWhat is Ozuriftamab?Ozuriftamab is an investigational monoclonal antibody targeting CD47, designed to enhance immune-mediated clearance of cancer c

Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What

What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c

Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses

Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate